Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab
Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.
You may also be interested in...
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
Twelve applications with September goal dates include six novel agents but only one breakthrough designation.
Emerging Company Profile: With experienced leadership and new financing, Evommune is developing a topical IRAK4 inhibitor for atopic dermatitis and earlier-stage systemic drugs for various conditions.